Organism Function

Odyssey Therapeutics Secures $213M Series D to Accelerate Autoimmune Clinical Portfolio

1 day ago talkbio0Tagged Autoimmune Diseases, clinical pipeline, Immunoregulation, Inhibitor, investors, Odyssey, Precision - temporal, preclinical programs, Protac, RIPK2, Series D financing, Technology

Odyssey Therapeutics; Series D financing; $213 million; autoimmune diseases; clinical pipeline; preclinical programs; precision immunomodulation; RIPK2 inhibitor; PROTAC technology; investors

Recent News on Scaling Up Cell & Gene Therapy Supply Chains (2025)

1 week ago talkbio0Tagged Automation, Cells, digital solutions, gene therapy, Growth, Logistics, Market, patient-specific therapies, risk mitigation, scalability, supply chain, white glove delivery

cell and gene therapy; supply chain; scalability; logistics; digital solutions; risk mitigation; white glove delivery; patient-specific therapies; automation; market growth

FDA Suspends Valneva’s Chikungunya Vaccine, Ixchiq, Due to Serious Safety Concerns

3 weeks ago talkbio0Tagged Adverse event, Cessation of life, chikungunya vaccine, Encephalitis, Hospitalization, Ixchiq, license suspension, Safety, United States Food and Drug Administration, Valneva

FDA; Valneva; Ixchiq; chikungunya vaccine; license suspension; safety; serious adverse events; encephalitis; hospitalizations; deaths

Teva Execs Shrug Off Pharmaceutical Tariff Threat as Turnaround Strategy Rolls Forward

1 month ago talkbio0Tagged earnings, Francis, Growth, operating profit margin, pharmaceutical tariffs, Pivot Device, Richard, supply chain, tariff threat, Teva, turnaround strategy

Teva; tariff threat; pharmaceutical tariffs; turnaround strategy; supply chain; pivot to growth; earnings; innovative medicines; Richard Francis; operating profit margin

CDMO Pulse Check: Lonza Posts Major Sales Rebound as Samsung Bio Keeps Revenue Growth Rolling

2 months ago talkbio0Tagged capsule (pharmacologic), CDMO, commercial, expansion, Growth, Lonza, Manufacturing, profit margin, Sales - occupational activity, Samsung Bio

Lonza; CDMO; sales growth; Samsung Bio; 2025 outlook; profit margin; Capsules & Health Ingredients; commercial momentum; manufacturing expansion

Sarepta Stands Behind Elevidys After FDA Requests Withdrawal Amid Safety Concerns

2 months ago talkbio0Tagged Cessation of life, Clinical Trials, concerns, ELEVIDYS, gene therapy, Market, Muscular Dystrophy, Duchenne, Safety, United States Food and Drug Administration, Withdraw (activity)

Sarepta; Elevidys; FDA; gene therapy; market withdrawal; safety concerns; Duchenne muscular dystrophy; deaths; clinical trial hold

Trump Threatens 200% Tariffs on Pharma Imports, Proposes 1-Year Grace Period for Onshoring

2 months ago talkbio0Tagged 200, Biopharma, drug imports, grace, Investments, Menstruation, onshoring, Pharma, pharmaceutical tariffs, Policy, tariff, Transplant Registry Unified Management Program, U.S.

Trump; pharmaceutical tariffs; 200% tariff; grace period; pharma manufacturing; drug imports; US supply chain; onshoring; policy; biopharma investments

Bristol Myers CEO: America’s Biopharma Leadership Not Guaranteed

4 months ago talkbio0Tagged Americas, Biopharma, CEO, Chris Boerner, dealmaking, global competitiveness, Growth, innovation, Myers, squibb

Bristol Myers Squibb; CEO; Chris Boerner; biopharma; Americas; global competitiveness; dealmaking; innovation; growth portfolio

Azafaros Raises €132M in Series B to Fund Phase 3 Trials for Brain-Penetrant Drug

4 months ago talkbio0Tagged Azafaros, Brain-Penetrant Drug, Capital, Clinical Trials, Forbion, Growth, Jeito, Lysosomal Storage Diseases, neuro-metabolic diseases, Neurodegenerative Disorders, nizubaglustat, Phase 3, Series B funding

Azafaros; Series B funding; nizubaglustat; brain-penetrant drug; lysosomal storage disorders; rare neuro-metabolic diseases; phase 3 clinical trials; Jeito Capital; Forbion Growth; neurodegenerative diseases

Pivotal readouts on deck as Takeda sees stagnant sales this year

4 months ago talkbio0Tagged Growth, JPY, Phase 3, Pivotal, Sales - occupational activity, Takeda

Takeda, Phase 3, Pivotal, Growth, Sales – occupational activity, JPY